A study exploring the safety and efficacy of Atezolizumab in combination with Obinutuzumab or Rituximab anti-CD20 therapy in participants with Relapse/Refractory Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL) and Waldenström Macrobulinemia (WM)
Cancer
For the latest version of this information please go to www.forpatients.roche.com